

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sinco Pharmaceuticals Holdings Limited**

**兴科蓉医药控股有限公司**

*(Incorporated under the laws of Cayman Islands with limited liability)*

**(Stock Code: 6833)**

**TRADING HALT**

At the request of Sinco Pharmaceuticals Holdings Limited (the “**Company**”), trading in the shares (stock code: 6833) of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 9:00 a.m. on Thursday, 6 October 2022 pending release of an announcement relating to inside information of the Company.

By order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 6 October 2022

*As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*